A Phase 1 Double-Blinded Trial to Evaluate Safety, Immunogenicity, and Dosing of Measles-Vectored Chikungunya Virus Vaccine (MV-CHIK) in Healthy Adults.

Patricia Winokur, Theresa E Hegmann, Hana M El Sahly, Evan J Anderson, DMID 15-0038 Study Group

Abstract readClinical Trial, Phase IRandomized Controlled Trial

In one paragraph

Trial report in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Mapping Human Clinical Evidence for Chikungunya Vaccines: A Scoping Review of Immunogenicity, Durability, and Safety.Vaccines · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Patricia WinokurUniversity of Iowa, Department of Internal Medicine, Iowa City, Iowa, USA.ORCID 0000-0002-4826-1790

Theresa E HegmannUniversity of Iowa, Department of Physician Assistant Studies, Iowa City, Iowa, USA.ORCID 0000-0002-6985-7964

Hana M El SahlyBaylor College of Medicine, Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0003-0489-0074

Evan J AndersonEmory University, Department of Medicine and Department of Pediatrics, Atlanta, Georgia.ORCID 0000-0002-1576-4420

DMID 15-0038 Study Group

Funding

Emory UniversityNational Institute of Allergy and Infectious DiseasesNIAID NIH HHS HHSN272201300015INIAID NIH HHS HHSN272201300018INIAID NIH HHS HHSN272201300020INIH HHS

6 · The paper itself

Abstract

This study of a measles-vectored vaccine for chikungunya virus (MV-CHIK) was a Phase 1 randomized, double-blinded, placebo-controlled trial with varying intervals between the 2 doses. The 6 cohorts each had 30 subjects, of which 25 received MV-CHIK and 5 received placebo. The 5 × 105 TCID50 dose was superior to the 5 × 104 TCID50 dose, and longer dosing intervals resulted in higher titers in the high dose groups. Mild to moderate injection site and systemic reactogenicity was common but brief. There was no evidence of prolonged vaccine-related arthralgia.

Indexed as

Chikungunya FeverChikungunya virusImmunogenicity, VaccineViral VaccinesAdolescentAdultAntibodies, ViralDouble-Blind MethodFemaleHealthy VolunteersHumansMaleMeasles virusMiddle AgedYoung AdultAntibodies, ViralViral Vaccineschikungunyameasles-vectored vaccinephase 1 trialvaccine

Identifiers

PMID41313671

DOI10.1093/infdis/jiaf571

PMCPMC13017142

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.